Predicting the course of disease in recurrent vulvar cancer - A subset analysis of the AGO-CaRE-1 study
Standard
Predicting the course of disease in recurrent vulvar cancer - A subset analysis of the AGO-CaRE-1 study. / AGO-CaRE 1 investigators.
In: GYNECOL ONCOL, Vol. 154, No. 3, 09.2019, p. 571-576.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Predicting the course of disease in recurrent vulvar cancer - A subset analysis of the AGO-CaRE-1 study
AU - Woelber, Linn
AU - Eulenburg, Christine
AU - Kosse, Jens
AU - Neuser, Petra
AU - Heiss, Christoph
AU - Hantschmann, Peer
AU - Mallmann, Peter
AU - Tanner, Berno
AU - Pfisterer, Jacobus
AU - Jückstock, Julia
AU - Hilpert, Felix
AU - de Gregorio, Nikolaus
AU - Iborra, Severine
AU - Sehouli, Jalid
AU - Ignatov, Atanas
AU - Hillemanns, Peter
AU - Fürst, Sophie
AU - Strauss, Hans-Georg
AU - Mahner, Sven
AU - Prieske, Katharina
AU - AGO-CaRE 1 investigators
N1 - Copyright © 2019 Elsevier Inc. All rights reserved.
PY - 2019/9
Y1 - 2019/9
N2 - OBJECTIVE: In vulvar cancer (VSCC), the course of disease with regard to localization of recurrence and relation of different recurrence sites is poorly described.METHODS: The AGO CaRE-1 study is a retrospective survey of treatment patterns and prognostic factors in vulvar cancer. Patients (pts) with primary VSCC, FIGO stage ≥1B treated in Germany from 1998 to 2008 were included in a centralized database (n = 1618). In the current subgroup analysis, different sites of primary recurrence and their impact on disease course and survival were analyzed using multistate and competing risks methods.RESULTS: 1249 pts with surgical groin staging and known lymph-node status (35.8% N+) were included in the analysis. 360 pts (28.8%) developed disease recurrence; thereof 193 (53.6%) at the vulva only, with a cumulative incidence of 12.6% after 2 years. Generally, prognosis after disease depended on recurrence site: Hazard ratios (HRs) (95% confidence interval) to die for pts with compared to without recurrence at the same time: vulvar only: 5.9 (4.3-8.2); groins only: 6.0 (3.0-10.2); vulvar and groins: 14.1 (7.6-26.4); pelvic/distant: 21.2 (15.3-29.4). Fifty-eight (30.1%) pts with local recurrence developed second recurrence. 2-year mortality after any recurrence was 56.3%. After vulvar recurrence pts had a 2-year and 5-year overall survival rate of 82.2% and 66.9%.CONCLUSIONS: Prognosis after recurrence is highly depending on recurrence site. Pts with isolated vulvar recurrence have an impaired prognosis as many affected pts develop second recurrences.
AB - OBJECTIVE: In vulvar cancer (VSCC), the course of disease with regard to localization of recurrence and relation of different recurrence sites is poorly described.METHODS: The AGO CaRE-1 study is a retrospective survey of treatment patterns and prognostic factors in vulvar cancer. Patients (pts) with primary VSCC, FIGO stage ≥1B treated in Germany from 1998 to 2008 were included in a centralized database (n = 1618). In the current subgroup analysis, different sites of primary recurrence and their impact on disease course and survival were analyzed using multistate and competing risks methods.RESULTS: 1249 pts with surgical groin staging and known lymph-node status (35.8% N+) were included in the analysis. 360 pts (28.8%) developed disease recurrence; thereof 193 (53.6%) at the vulva only, with a cumulative incidence of 12.6% after 2 years. Generally, prognosis after disease depended on recurrence site: Hazard ratios (HRs) (95% confidence interval) to die for pts with compared to without recurrence at the same time: vulvar only: 5.9 (4.3-8.2); groins only: 6.0 (3.0-10.2); vulvar and groins: 14.1 (7.6-26.4); pelvic/distant: 21.2 (15.3-29.4). Fifty-eight (30.1%) pts with local recurrence developed second recurrence. 2-year mortality after any recurrence was 56.3%. After vulvar recurrence pts had a 2-year and 5-year overall survival rate of 82.2% and 66.9%.CONCLUSIONS: Prognosis after recurrence is highly depending on recurrence site. Pts with isolated vulvar recurrence have an impaired prognosis as many affected pts develop second recurrences.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Cohort Studies
KW - Female
KW - Humans
KW - Kaplan-Meier Estimate
KW - Lymph Nodes/pathology
KW - Middle Aged
KW - Multivariate Analysis
KW - Neoplasm Recurrence, Local/pathology
KW - Neoplasm Staging
KW - Prognosis
KW - Proportional Hazards Models
KW - Retrospective Studies
KW - Survival Rate
KW - Vulvar Neoplasms/pathology
KW - Young Adult
U2 - 10.1016/j.ygyno.2019.07.009
DO - 10.1016/j.ygyno.2019.07.009
M3 - SCORING: Journal article
C2 - 31324454
VL - 154
SP - 571
EP - 576
JO - GYNECOL ONCOL
JF - GYNECOL ONCOL
SN - 0090-8258
IS - 3
ER -